The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | NKTR-255 in R/R MM and NHL
Nina Shah, MD, University of California-San Francisco, San Francisco, CA, outlines a phase I, dose escalation and expansion study (NCT04136756) of NKTR-255, a polymer-conjugated IL-15, as a single agent in relapsed/refractory multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), plus in combination with daratumumab as a salvage regimen for MM. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
